ADMA ADMA Bio: רווח למניה בשנים עשר החודשים האחרונים

The annual revenue per unit for ADMA Biologics, as calculated by GURU.Markets quotes, reaches 0.78, which characterizes this valuation parameter. The growth of ADMA Biologics relies on strict FDA control and unique plasma purification patents. However, the business faces pressure from synthetic analogs and market oligopoly, while simultaneously reducing dependence on external laboratories through the localization of supply chains.

ADMA Biologics' proprietary plasma collection centers and patent protection generate high margins that translate directly into earnings per share growth. By analyzing the TTM net income per share distribution on the GURU.Markets platform, an investor can see the total annual income adjusted for share issuance volume, allowing for an objective assessment of the real cost of capital and the risks of buying at local peaks.